A possible novel mechanism of opportunistic infection in systemic lupus erythematosus, based on a case of toxoplasmic encephalopathy.
N
N
Seta
T
T
Shimizu
M
M
Nawata
R
R
Wada
K
K
Mori
I
I
Sekigawa
N
N
Iida
M
M
Maeda
H
H
Hashimoto
D000328:Adult; D000818:Animals; D000890:Anti-Infective Agents / Q000627:therapeutic use; D000913:Antibodies, Protozoan / Q000097:blood; D002540:Cerebral Cortex / Q000000981:diagnostic imaging / Q000473:pathology; D004338:Drug Combinations; D005260:Female; D006801:Humans; D016867:Immunocompromised Host; D008180:Lupus Erythematosus, Systemic / Q000150:complications* / Q000188:drug therapy / Q000473:pathology; D009894:Opportunistic Infections / Q000150:complications* / Q000188:drug therapy / Q000473:pathology; D011239:Prednisolone / Q000627:therapeutic use; D011739:Pyrimethamine / Q000627:therapeutic use; D013413:Sulfadoxine / Q000627:therapeutic use; D013422:Sulfamonomethoxine / Q000627:therapeutic use; D014057:Tomography, X-Ray Computed; D014122:Toxoplasma / Q000276:immunology / Q000302:isolation & purification*; D016781:Toxoplasmosis, Cerebral / Q000150:complications* / Q000188:drug therapy / Q000473:pathology; D016896:Treatment Outcome
D000890:Anti-Infective Agents; D000913:Antibodies, Protozoan; D004338:Drug Combinations; C001205:fanasil, pyrimethamine drug combination; D013413:Sulfadoxine; D011239:Prednisolone; D013422:Sulfamonomethoxine; D011739:Pyrimethamine